請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10251
標題: | 在人類臍靜脈內皮細胞中NF-κB在黃體素誘導p53向上調節的角色 Role of NF-κB in regulating the progesterone-induced p53 up-regulation in HUVEC |
作者: | Ho-Ching Yang 楊和慶 |
指導教授: | 李文森(Wen-Sen Lee) |
共同指導教授: | 胡孟君(Meng-Chun Hu) |
關鍵字: | 黃體素,黃體素受器,NF-κB,IκBα,p53, Progesterone,Progesterone receptor,NF-κB,IκBα,p53, |
出版年 : | 2011 |
學位: | 碩士 |
摘要: | 內皮細胞參與多樣化的生理過程,包括血管生成、止血及發炎。在本實驗室先前研究指出,黃體素在生理濃度下(500 nM)會抑制人類臍靜脈內皮細胞的增生,此種抑制作用是透過增加p53的表現來達成。在給予黃體素處理後的十分鐘內就可觀察到細胞內磷酸化的ERK蛋白質量的增加,但是黃體素處理後所誘導的p53增加則在給藥後二十三小時才會出現。使用NCBI資料庫分析,發現p53基因啟動子上面有NF-κB、HLH及EBPβ等轉錄因子結合位置,在許多細胞內轉錄因子當中,NF-κB被認為與血管細胞血管增生功能有密切關係,本篇的研究主題是觀察NF-κB在黃體素誘導p53向上調節所扮演的角色。經由分析細胞中蛋白質表現量發現,黃體素並不會刺激細胞內NF-κB的總量增加,但是在黃體素誘導p53蛋白表現量增加之前的時間點可觀察到IκBα有被磷酸化的現象,之後NF-κB經由細胞質進入細胞核,增加NF-κB與p53基因的結合,影響p53的表現。使用NF-κB抑制劑Bay11-7082可以減少黃體素增加p53的表現。本實驗室的先前研究結果顯示黃體素是透過活化ERK路徑,增加p53蛋白的表現。本研究給予ERK-1/2抑制劑 U0126或PD98059會減少IκBα的磷酸化作用,顯示黃體素增加IκBα的磷酸化作用是透過活化ERK。利用基因序列刪除法,我們的實驗結果顯示NF-κB結合位置對於黃體素誘導p53啟動子活性具有決定性的角色,而HLH及EBPβ結合位置對於p53基因啟動子也提供部份調節的作用。我們的研究亦發現黃體素受器PR-A,在經過黃體素刺激後會進入細胞核內,而PR-B沒有出現這種現象;從免疫共沈澱的實驗結果中,發現到NF-κB與PR-A的結合有增加的現象,而這二者因子結合增加的現象,暗示PR-A可能會調節NF-κB的作用來調控p53的表現,進而抑制血管內皮細胞的增生。 Endothelial cells are involved in a diversity of physiologic processes including angiogenesis, hemostasis, and inflammation. Previously, our laboratory has demonstrated that progesterone at a physiological concentration (500 nM) inhibited proliferation of human umbilical venous endothelial cells (HUVEC) through a p53-dependent pathway and the ERK-mediated pathway is involved in the progesterone-induced increase of p53. The progesterone-induced increase of the level of phosphorylated ERK was observed at 10 min after treatment, while the increased p53 level was not observed until 23 h after treatment. Based on the NCBI database, the human p53 gene promoter contains three transcription factor binding sites including NF-κB, HLH, and EBPβ. It has been indicated that NF-κB might be involved in the regulation of angiogenesis. Accordingly, the aim of this study is to investigate how NF-κB regulates p53 in HUVEC. Our data showed that the total protein levels of NF-κB in progesterone-treated HUVEC were not changed significantly. However, progesterone increased IκBα phosphorylation as well as NF-κB nuclear translocation and binding onto the p53 promoter. Treatment of HUVEC with NF-κB inhibitor, Bay11-7082, reduced the progesterone-induced increase of p53, suggesting that progesterone induced increase of p53 through increase of IκBα phosphorylation, which in turn increased NF-κB nuclear translocation and binding onto the p53 promoter. Treatment of HUVEC with an ERK inhibitor, U0126 or PD98059, reduced the progesterone-induced increase of IκBα phosphorylation, suggesting that progesterone increased IκBα phosphorylation through the ERK pathway. Using gene deletion, our data suggest that the NF-κB binding site on the p53 gene promoter is essential for progesterone-induced p53 up-regulation, wherease the HLH and EBPβ binding sites might also play important roles in regulating the p53 promoter activity. Progesterone receptor-A (PR-A), but not PR-B, translocated into the nucleus after treatment with progesterone. Immunoprecipitation showed that progesterone increased the binding between NF-κB and PR-A. These results suggested that PR-A might participate in NF-κB-regulated p53 expression and further inhibited the proliferation of vascular endothelial cells. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10251 |
全文授權: | 同意授權(全球公開) |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf | 6.32 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。